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Abstract 
Background: Cardiometabolic disease is more common in patients with schizophrenia than the general population.
Aim: The purpose of the study was to assess lifestyle factors, including diet and exercise, in patients with schizophre-
nia and estimate the prevalence of metabolic syndrome.
Methods: This is a cross-sectional study of a representative group of outpatients with schizophrenia in Salford, UK. 
An interview supplemented by questionnaires was used to assess diet, physical activity, and cigarette and alcohol 
use. Likert scales assessed subjects’ views of diet and activity. A physical examination and relevant blood tests were 
conducted.
Results: Thirty-seven people were included in the study. 92% of men had central adiposity, as did 91.7% of women 
(International Diabetes Federation Definition). The mean age was 46.2 years and mean illness duration was 11.6 years. 
67.6% fulfilled criteria for the metabolic syndrome. The mean number of fruit and vegetable portions per day was 
2.8 ± 1.8. Over a third did not eat any fruit in a typical week. 42% reported doing no vigorous activity in a typical 
week. 64.9% smoked and in many cigarette use was heavy. The Likert scale showed that a high proportion of patients 
had insight into their unhealthy lifestyles.
Conclusions: Within this sample, there was a high prevalence of poor diet, smoking and inadequate exercise. Many 
did not follow national recommendations for dietary intake of fruit and vegetables and daily exercise. These factors 
probably contribute to the high prevalence of metabolic syndrome. Many had insight into their unhealthy lifestyles. 
Thus, there is potential for interventions to improve lifestyle factors and reduce the risk of cardiometabolic disease.
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Background
People with schizophrenia suffer from increased mor-
bidity and mortality compared with the general popula-
tion, having a life expectancy that is approximately 20% 
shorter [1]. The excess mortality is largely due to cardio-
vascular disease (CVD). Furthermore, people with schiz-
ophrenia and other severe and enduring mental illnesses 
(SMI) are twice as likely to die from CVD compared with 
those in the general population [2–4], and the excess 
mortality is higher in younger individuals. Known risk 
factors for CVD include smoking, being overweight, 
inadequate exercise and a low intake of fruit and vegeta-
bles [5]. These lifestyle risk factors are more common in 
people with schizophrenia than in the general population 
[6–9].
In a North-American review, 42% of individuals with 
schizophrenia were reported to be obese [body mass 
index (BMI)  ≥27  kg/m2] compared with 27% of the 
general population [6]. McCreadie and colleagues [7, 
8] showed that the diets of people with schizophrenia 
in Scotland were less healthy than those of the general 
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population on a range of parameters. Short-term efforts 
to improve diet in individuals with schizophrenia have 
been shown to be of only limited benefit [10] with the 
implication that any intervention must be long-term to 
be effective. Studies have repeatedly reported high rates 
of smoking in those with schizophrenia [8]. Information 
about exercise levels in schizophrenia is scanty, but clini-
cal experience suggests it is often poor.
The high prevalence of poor diet, inadequate exercise 
and obesity in schizophrenia may partly reflect the asso-
ciated socio-economic disadvantages of the illness, and 
many sufferers are unable to gain paid employment. In 
addition, core psychiatric symptoms including avolition 
and tiredness may contribute. Antipsychotic medication 
can cause metabolic derangements, including hypergly-
cemia and hyperlipidaemia [11, 12] as well as weight gain 
[12, 13] which if sustained can contribute to CVD. Other 
psychiatric medications, including mood stabilisers and 
some antidepressants, can also cause weight gain [2]. In 
summary, the excess of CVD in schizophrenia appears 
multifactorial.
Given the evidence of suboptimal lifestyle choices in 
people with SMI, the aims of this study were to deter-
mine the pattern of dietary intake and exercise in a repre-
sentative group of individuals with schizophrenia in a UK 
inner city area and to determine whether age predicted 
the presence of metabolic syndrome in this group.
Methods
The study was carried out at two Community Mental 
Health Centres in Salford, an inner city area in North 
West England, UK. The study was approved by the local 
Salford Ethics Committee and the Trust Research and 
Development Department. All outpatients aged between 
16 and 65 years of age who were prescribed a neuroleptic 
drug and had a diagnosis of schizophrenia or schizoaffec-
tive disorder were eligible to enter the study. A series of 
consecutive outpatients were asked to consider entering 
the study. The majority of participants (23 out of 37) were 
living alone.
With regard to the characteristics of responders vs 
non-responders, in relation to clinical variables, for those 
non-responders for whom data are available (21 service 
users), there was no significant difference in age, BMI, 
blood glucose, and cholesterol level between the groups.
Patients who consented attended for a single assess-
ment in a fasted state (i.e. not having had anything to eat 
since 22.00 h the night before). They completed a short 
interview to assess diet and activity in the previous week 
(Additional file  1). Assessment of diet and exercise was 
based on validated assessment tools [14]. Activity was 
rated as vigorous or moderate using the definitions given 
in Additional file 1. Subjects also completed Likert scales 
(rated 1–10) that assessed their views of diet, activity and 
medication compliance.
Each participant underwent basic anthropometric 
measurements, namely height, weight, and waist: hip 
ratio. Pulse and blood pressure were checked using a 
validated semi-automatic Omron HEM-705CP moni-
tor (Omron Healthcare, Kyoto, Japan). The interviews 
and anthropometric measurements were undertaken by 
one of two trained research nurses. Socio-demographic 
details, details of psychiatric and medical history, and 
current prescribed medication were taken from the med-
ical notes.
A fasting blood sample was taken for a variety of bio-
chemical tests including serum glucose, lipids and prol-
actin. Apart from prolactin measurement, all assays were 
performed on the Roche Modular System (Burgess Hill, 
West Sussex, UK). Prolactin was assayed on the Siemens 
Immulite 2000 automated analyser (Siemens Healthcare 
Diagnostics, Frimley, Camberley, Surrey, UK).
Metabolic syndrome definition
According to the 2005 IDF definition [15], for a person to 
be defined as having the metabolic syndrome they must 
have the following:
Central obesity (defined as waist circumfer-
ence ≥94  cm for European men and ≥80  cm for Euro-
pean women, with ethnicity specific values for other 
groups, specifically 90 cm for South Asian and Oriental 
origin men) plus any two of the following four factors (all 
but two of the participants in this study were of European 
origin):
  • raised TG level: ≥150  mg/dL (1.7  mmol/L), or spe-
cific treatment for this lipid abnormality
  • reduced HDL cholesterol: <40 mg/dL (1.03 mmol/L) 
in males and <50 mg/dL (1.29 mmol/L) in females, or 
specific treatment for this lipid abnormality
  • raised blood pressure: systolic BP ≥ 130 or diastolic 
BP  ≥  85  mmHg, or treatment of previously diag-
nosed hypertension
  • raised fasting plasma glucose (FPG)  ≥100  mg/dL 
(5.6 mmol/L), or previously diagnosed type 2 diabe-
tes if >5.6 mmol/L or 100 mg/dL.
Results
Sample characteristics
The response rate among those eligible to enter the study 
was 41%. Twenty-five men and twelve women partici-
pated in the study. All had schizophrenia or schizoaffec-
tive disorder.
The mean duration of illness was 11.6 years (95% con-
fidence interval: 7.3–18.2). The mean age was 46.2 years 
(46.2–49.2). Of the group, 30 (81%) were unemployed, 
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four were in paid employment, one was in voluntary 
employment, one was retired, and one was off work due 
to sickness at the time of interview. The majority of par-
ticipants (35 out of 37) were of White European origin, 
with one of South Asian ethnicity, and one of Chinese 
ethnicity. In keeping with the protocol, all patients were 
taking neuroleptic medication. The key results are sum-
marised in Table 1.
Of the participants, 20 out of 37 were taking oral atypi-
cal agents (eight were taking Clozapine) with 13 on depot 
neuroleptics (of which two were receiving depot Risperi-
done) and four on mood stabilisers as the primary psy-
chotropic agent.
Smoking and alcohol use
Twenty-four out of 37 subjects (64.9%) were cur-
rent smokers, six (16.2%) were ex-smokers with seven 
(18.9%) never having smoked. Of the current smokers, 
four smoked between 1 and 10 cigarettes per day, nine 
between 11 and 20 cigarettes per day, and eleven between 
21 and 60 cigarettes per day. 15% of male subjects con-
sumed above the recommended safe levels of alcohol in 
a week (21 units per week). No women consumed above 
the recommended safe levels of alcohol in a week (14 
units per week). Of the total sample of 37 patients, 14 
took no alcohol in a week.
Weight and related measurements
Within the group, BMI ranged from 18.4 to 52.4  kg/m2 
(normal range: 18.5–25.0  kg/m2; World Health Organi-
sation [16]). Mean (95% CI) BMI for men was 31.2 
(28.2–34.3) kg/m2, and for women was 31.8 (26.3–37.3) 
kg/m2. 47.2% of the group had a BMI in the obese range 
(≥30.0 kg/m2). Thirty-two (86.5%) reported that they did 
not find it difficult to put on weight.
For men (all of White European origin), mean (95% CI) 
waist circumference was 106.9 (100.8–112.9) cm (Fig. 1). 
For Caucasian men, central adiposity is defined as 
waist ≥94 cm [15]. For men (one was South Asian), waist 
circumference was 96.5 (86.7–106.3) cm (Fig.  1). For 
women of European and South Asian ethnicity, central 
adiposity is defined as waist ≥80 cm [16]. 92.0% of men 
had central adiposity as defined, as did 91.7% of women.
Pulse and blood pressure
Mean (±SD) systolic blood pressure was 126 ± 19 mmHg 
and mean diastolic blood pressure was 80 ± 13 mmHg. 
21.6% had a systolic blood pressure  >140  mmHg and 
45.9% a diastolic blood pressure >80 mmHg.
Laboratory results
Four out of 37 patients were known to have diabetes, 
and three of the 37 patients (8.1%) had a fasting glucose 
between 6.1 and 6.9  mmol/L [17]. Fasting total choles-
terol was  >5  mmol/L in 48% of individuals with fasting 
LDL-cholesterol  >3  mmol/L in 43.3% of patients. 16.7% 
of the patients had a serum prolactin  >1000  μL, the 
threshold agreed by local endocrine services as meriting 
further investigation.
Metabolic syndrome
Twenty-five patients (67.6%) would be categorised as 
having the metabolic syndrome using the International 
Diabetes Federation (IDF) Criteria [15]. This was more 
likely if the individual was older (odds ratio 1.4 (95% CI 
1.32–1.48).
Diet
Thirty-two participants completed the dietary question-
naire. A total of 13.5% of participants ate ≥5 portions of 
fruit and vegetables per day. Mean (±SD) portions of fruit 
per day were 1.1 ± 1.0 and of vegetables were 1.7 ± 1.2. 
Total fruit and vegetable portions were 2.8 ± 1.8. For the 
group, oily fish was eaten on average on 0.5 ± 0.6 days of 
each week.
Fruit was only eaten on ≥3  days each week by 34.4% 
of the group, with 37.5% reporting not eating fruit on 
Table 1 Details of sample and key results
Socio-demographic factors Number and  % of patients
(unless otherwise specified)
Mean age (95% CI), yrs 46.2 (43.2–49.2)
Male (%) 25 (67.6)
Mean duration of illness (95% CI), yrs 11.6 (7.3–18.2)
Caucasian (%) 35 (94.6)
Lifestyle parameters
5 portions or more of fruit and vegeta-
bles per day (%)
13.5
Fresh fruit at least once a week (%) 62.5
Vigorous exercise taken once a week 
for ≥10 min (%)
29
BMI ≥30 (%) 47.2
Current smoker (%) 64.9
Weekly alcohol > safe limits (%) 15
Blood parameters
Fasting glucose elevated >6.0 mmol/L 
(%)
21.2
Cholesterol >5 mmol/L (%) 48
Prolactin elevated >1000 mu/L (%) 16.7
Miscellaneous
Blood pressure >140/90 mmHg (%) 32.4
Metabolic syndrome (%) 67.6
Regard diet as unhealthy (%) 54.1
Regard themselves as physically inactive 
(%)
51.4
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any day of the week (Table  2). Vegetables were eaten 
on ≥3 days of each week by 59.4% of individuals.
With regard to takeaway foods, twelve (37.5%) did not 
have any in the previous week, 18 (56.3%) had 1–2 takea-
ways and two (6.3%) had >2 takeaways. For ready meals, 
the breakdown was similar with 50% (16 out of 32) hav-
ing none, 34.4% (11/32) having 1–2 ready meals, 9.4% (3 
out of 32) having 3–4 ready meals but 6.3% (2 out of 32) 
having ≥7.
For crisps, 18 out of 32 (56.3%) had no crisps in the last 
week and for bread 56.3% (18 out of 32) had white bread, 
13 wholemeal/granary bread/brown bread, and one had 
no bread.
Activity
41.9% of participants reported doing no vigorous activ-
ity in the last week (see Additional file 1 for definition). 
35.5% did <1 h of vigorous activity per week. Only 29% 
did ≥10 min of vigorous activity per week. 29% described 
doing no moderate activity in any week and 39% of 
patients did so for <1 h per week (Fig. 2). Of 31 respond-
ers, 21 walked for <1 h each day, 14 said that they walked 
for ≥10 min each day with five walking once or not at all 
in any week, and the remaining twelve walking 2–6 times 
each week for >10 min.
Likert scale ratings
The people studied displayed an understanding that their 
lifestyle was less healthy than might be achieved, in terms 
of both diet and exercise.
Diet
Patient ratings on a visual scale of 1–10 for the ques-
tion ‘Would you describe your diet as healthy (average 
over the last 3 months)?’ gave a mean ± SD of 5.7 ± 2.2. 



















Fig. 1 Distribution of waist circumference for men and women. The 80 and 94-cm marks on the figure indicate the cut points for the International 
Diabetes Federation [15] definition of central adiposity




% of group Number of days 
eating fruit
% of group
0 12.5 0 37.5
1–2 28.1 1–2 28.1
3–5 34.4 3–5 18.8
>5 25.0 >5 15.6
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Activity
Patient ratings on a visual scale of 1–10 for the ques-
tion ‘Would you consider yourself fairly physically active 
(average over the last 3 months)?’ gave a mean ± SD of 
5.0  ±  2.9. The anchor points were 0  =  very physically 
inactive, 10 = very physically active.
Medication compliance
Patient ratings on a visual scale of 1–10 for the ques-
tion ‘Are you compliant with medication prescribed for 
you to take (over the last 3 months)?’ gave a mean ± SD 
of 9.8 ± 0.8. The anchor points were 0 = not compliant, 
10 = very compliant.
If a score of  <5.0 on the Likert scales is used to indi-
cate that a patient does not think they have a healthy diet, 
and a score <5.0 as a patient regarding themselves as not 
physically active, then the percentage of patients who 
accepted that they had a problem in these two areas was 
54.1 and 51.4%, respectively.
Discussion
We report three important findings from this study: (i) a 
high prevalence of metabolic syndrome; (ii) a high preva-
lence of poor diet, smoking and inadequate exercise; and 
(iii) that a high proportion of patients have insight into 
their unhealthy lifestyles. In relation to the third finding, 
we believe that an insight into lifestyle has not previously 
been reported. The fact that our subjects showed some 
degree of insight into their lifestyle problems indicates 
that there is potential for working with this group to 
improve the quality of diet and to increase the amount of 
exercise taken each day [10, 18].
In terms of methodology, the study sample was small 
but it is representative of patients with schizophrenia 
and schizoaffective disorder. In the current study, we 
approached a consecutive series of outpatients and just 
over 40% took part in the study. This is comparable with 
contemporary analysis of rates of screening in UK Pri-
mary Care [19].
If there is a sampling bias, it is likely that more moti-
vated patients with healthier lifestyles took part. Patients 
were asked to attend in a fasted state and this was 
checked with them on the day that they attended. All 
anthropometric measurements were taken by one of 
two trained research nurses ensuring accuracy and con-
sistency. The cut-offs that were used to define insight 
into lifestyle on the Likert scales have not been formally 
assessed; however, assessment of diet and exercise was 
based on validated assessment tools [14].
The prevalence of metabolic syndrome in our group 
was 67.6%. This is a major concern because metabolic 
syndrome is a strong predictor of CVD [15, 19, 20] and 
of cardiovascular death [21]. The rates of metabolic syn-
drome are similar to other studies. In terms of compo-
nents of the metabolic syndrome, most patients had a 
BMI and waist circumference above normal thresholds, 
with 92% of both men and women having central adipos-
ity. Perhaps surprisingly, only a fifth of patients had an 
elevated systolic blood pressure.
Many individuals did not follow the recommenda-
tions for dietary intake of fruit and vegetables [22]. A 
significant proportion did not exercise as much as is 
recommended [17]. Levels of smoking were high. These 
results mirrored the seminal work done on lifestyle in 
schizophrenia conducted by McCreadie et  al. [7] in the 
1990s and subsequently [8, 9]. It is of concern that there 
has been no improvement in the intervening period. In 
particular, the last decade has seen investment in strate-
gies to reduce smoking in the general population which 
have been successful. In contrast, smoking levels remain 
high in those with SMI. Our data show that the problems 
noted by McCreadie [8] in a Scottish sample, namely high 
levels of smoking, poor diet and low levels of exercise are 
also seen in England, increasing the likelihood that these 
findings represent the national picture.
Regular health screening, including measurement of 
fasting lipids and glucose, is recommended for those with 
SMI and those treated with antipsychotics in many treat-
ment guidelines [23]. In addition, it is generally agreed 
that lifestyle interventions are necessary to improve 
physical health of SMI patients [24, 25]. In non-psychi-
atric patients at high risk of developing diabetes, simple 
lifestyle adjustments have been shown to reduce diabetes 
risk. These interventions include decreasing calorific and 
fat content of food and increase fibre intake, increasing 
Fig. 2 Moderate exercise activities (hours per week) in a typical week
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intake of fruit and vegetables, eating complex rather than 
simple carbohydrates (e.g. whole-wheat bread rather 
than refined white bread) and avoiding sugary drinks, as 
well as carrying out exercise for at least 10–15  min per 
day. Advice to the general population to improve fruit 
and vegetable intake has been shown to be successful, at 
least in the short term [26].
In an intervention study [9], the diet of people with 
schizophrenia improved when they were given free fruit 
and vegetables; however, this was not sustained after 
withdrawal of the intervention, although there was a 
trend for the return to pre-intervention consumption 
to be more gradual when the free food intervention was 
combined with dietary advice.
A significant proportion of patients in our study had 
hyperprolactinaemia. This is a recognised adverse effect 
of many antipsychotics [27, 28]. The propensity to cause 
hyperprolactinaemia varies significantly between dif-
ferent atypical antipsychotics. Raised prolactin can be 
asymptomatic, leading to various acute adverse effects, 
and can also result in long-term medical problems, 
including osteoporosis.
We do not have a direct comparison group from the 
general population. However, a detailed survey of the 
Salford UK population in terms of lifestyle is underway 
(www.citizenscientist.org.uk). The majority of the par-
ticipants were living alone, so collection from someone 
cohabiting with them was not possible.
It could be argued that the quality of diet found in our 
study group is not significantly different from that of peo-
ple in a similar socio-demographic situation [29]. How-
ever, the high rates of diabetes and cardiovascular events 
[2–4] in SMI define them as a high-risk group for cardio-
metabolic disease and, as such, there is the potential for 
targeted intervention to produce benefit.
We recommend the following principles of manage-
ment to reduce cardiometabolic risk:
  • Potential pre-diabetes states should be investigated 
and managed as per agreed guidelines for the general 
population but with annual screening for this recom-
mended for those with psychosis receiving antipsy-
chotic medications. The prescription of metformin 
for those not responding to or not adherent to inten-
sive lifestyle interventions needs to be considered in 
the context of the individual service user.
  • Diabetes should be managed by the family practi-
tioner or a specialist physician where necessary.
  • Dyslipidemia, especially in the context of a patient 
with diabetes, should be actively managed accord-
ing to existing guidelines for the general population. 
There is no contra-indication to the prescription of 
a statin.
  • Hypertension should be managed according to 
national guidelines. There is no contra-indication to 
prescription of antihypertensive medications.
  • Smoking is an important additive risk factor for dia-
betes and cardiovascular disease and service users 
who smoke should be referred to smoking cessation 
services.
Our data show that there is scope to achieve a more 
healthy lifestyle in individuals with SMI. Such improve-
ments require collaboration between local Mental Health 
providers and General practitioners plus specialist ser-
vices, particularly dietetics, community health trainers 
and occupational therapy. It is likely that in many areas of 
the UK, and elsewhere, significant healthcare system re-
design will be necessary to achieve this goal [30].
One of the founding principles of the NHS in 1948 was 
that it should strive to improve the health of the individ-
ual and the population and prevent disease. The needs of 
the service users lie at the heart of this fundamental mis-
sion and of other healthcare providers across the world 
responsible for the welfare of patients with schizophrenia 
and other forms of severe enduring illness.
Conclusions
Within this sample, there was a high prevalence of poor 
diet, smoking and inadequate exercise. Many did not fol-
low national recommendations for dietary intake of fruit 
and vegetables and daily exercise. These factors probably 
contribute to the high prevalence of metabolic syndrome. 
Many had insight into their unhealthy lifestyles. Thus, 
there is potential for interventions to improve lifestyle 
factors and reduce the risk of cardiometabolic disease.
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